Misses etiketine sahip kayıtlar gösteriliyor. Tüm kayıtları göster
Misses etiketine sahip kayıtlar gösteriliyor. Tüm kayıtları göster

11 Ağustos 2016 Perşembe

NHS misses key targets in June as service faces increasing demand

The number of patients who were medically fit to leave hospital but could not be safely discharged reached a record high in June as NHS England continued to creak under the strain of increasing demand.


Targets to reach patients quickly enough after a 999 call and treat patients in A&E within four hours continued to be missed, and there were 3.63 million people on the waiting list for non-urgent care in hospital, usually elective operations.


The worrying figures emerged after the NHS had its busiest June on record, with more than 1.9 million A&E attendances, up by 2.1% on the same month last year, and more than 480,000 emergency admissions, 4.7% higher than in June 2015.


The NHS Confederation chief executive, Stephen Dalton, said: “These figures once again illustrate the strain the NHS is under to maintain timely access to high standards of care in the face of huge financial pressures.


“Our staff on the frontline are working flat out and deserve recognition for the dedication they display, day in, day out. But unless we break the cycle, performance results will continue to follow this downward trend.


“The recent and important relaxation of some targets, and of the penalties for missing them, will give many hospitals much-needed opportunity.


“We now need the government to incentivise greater coordination between local authorities and the NHS, and to invest more in out-of-hospital health and care.”


There were 6,105 patients delayed in hospital when medically fit to be discharged in June, often because social care support was not available, compared with 6,045 in May. The number of days lost to delayed transfers of care was 171,298, the second highest recorded, below only the total of 171,452 in May.


Hospital A&E departments admitted, transferred or discharged 85.8% of patients within the required four hours, well below the target of 95%. The number of patients waiting longer than four hours, 181,535, has almost doubled in the past year, from 96,663 in June 2015. Earlier this week, medics’ representatives warned that hospital emergency wards are in crisis as the supply of doctors fails to keep pace with demand for their services.


Nearly one-third of critically ill patients had to wait more than eight minutes for an ambulance to arrive in June. The national target is for no more than 25% of critically ill patients to wait this long.


The objective for non-urgent care was also not achieved, with 91.5% of patients waiting 18 weeks or less for treatment, below the 92% target.


The Labour leadership candidate Owen Smith said: “Waits for ambulances are going up, A&E departments are bursting at the seams and cuts to social care have left older people trapped on hospital wards for weeks or even months at a time.


“I won’t sit back and allow the Tories to destroy one of Labour’s greatest creations. That is why, if I am elected Labour leader and then prime minister, I would introduce a wealth tax on the richest 1% of people to fund a 4% annual increase in NHS funding.”


Matthew Swindells, NHS England’s national director for operations and information, said frontline services were improving in the face of intense pressure. “We continue to admit, treat or discharge more than nine out of 10 emergency patients within the four-hour target time,” he said.


A Department of Health spokesman said almost 60,000 people a day were seen in A&E within four hours and there were 1,250 extra doctors working in emergency departments compared with 2010.


“We are committed to delivering a safer, seven-day NHS, which is why we have invested £10bn to fund the NHS’s own plan to transform services in the future,” the spokesman said.



NHS misses key targets in June as service faces increasing demand

17 Mart 2014 Pazartesi

Phase 4 Actelion Review Misses Major Endpoint

Actelion Actelion announced nowadays that a phase four review with its blockbuster drug bosentan (Tracleer) had failed to meet its main endpoint.


The COMPASS-2 trial was a prospective, randomized, double-blind, placebo-controlled trial evaluating the result of bosentan on the time to very first confirmed event in patients with symptomatic pulmonary arterial hypertension (PAH) previously receiving treatment with sildenafil.


According to the firm, a 17% danger reduction in the principal endpoint of the time to initial event did not reach statistical significance (p=.25). Actelion reported that an exploratory examination showed a significant increase in the 6 minute strolling distance in the mixture group and “and a placebo-corrected incidence of 15.four%” in elevated liver enzymes above 23 months of treatment method.



The press release quoted the University of Michigan’s Vallerie McLaughlin, chair of the trial’s steering committee: “While the observed threat reduction of 17% did not reach statistical significance, I am convinced that this review supplies crucial data for the scientific local community and we are committed to execute all the needed analyses to totally comprehend the end result of the review.”


The company said that the total final results of the review will be presented at potential congresses and in peer-reviewed publications.


John Ryan, a pulmonary hypertension expert at the University of Utah, presented the following viewpoint:



“The COMPASS-2 trial assessed the efficacy of a common clinical practice, namely the addition of bosentan (an endothelia receptor antagonist, ERA) to sufferers with pulmonary arterial hypertension (PAH) already taking sildenafil (phosphodiesterase five inhibitor, PDE5i). The security and benefit (or otherwise) of this mixture treatment has been largely unknown. But because this illness process can advance so quickly with a limited life expectancy, if patients are deemed to be failing monotherapy with clinical deterioration, most PAH providers are aggressive in adding on a 2nd agent. For that reason the COMPASS-2 trial represents a marked advance in our information of the merits of dual treatment. Searching forward, it will be critical to complete similar combination trials with the other classes of agents accessible, especially ERAs and the new soluble guanylate cyclase stimulators (riociguat being the only currently available agent).”





Phase 4 Actelion Review Misses Major Endpoint